
TMO Stock Forecast & Price Target
TMO Analyst Ratings
Bulls say
Thermo Fisher Scientific is projected to experience stable revenue growth across its various segments, with lab products and services (LPBS) expected to increase at a compound annual growth rate of 5.4% over the next three years. The company is anticipated to capitalize on favorable trends in biopharma clinical trial outsourcing, as survey respondents indicated a significant intention to increase outsourcing in both early-stage and late-stage drug development. Additionally, analytical instruments revenue is forecasted to grow at a compound annual rate of 2.5%, reflecting the company's continued strategic positioning and competitive advantages within its market segments.
Bears say
Thermo Fisher Scientific has experienced a substantial decline in its adjusted EBIT margin, dropping approximately 830 basis points to 22.6% from 2021 to 2024. This downturn is attributed to a significant reduction in the adjusted gross margin, which decreased by about 940 basis points to 42.2%, and is approximately 420 basis points lower than the gross margin recorded in 2019. The deterioration in these key financial metrics indicates fundamental challenges within the company's operations, contributing to a negative outlook for its stock.
This aggregate rating is based on analysts' research of Thermo Fisher Scientific and is not a guaranteed prediction by Public.com or investment advice.
TMO Analyst Forecast & Price Prediction
Start investing in TMO
Order type
Buy in
Order amount
Est. shares
0 shares